Gilead Sciences, Inc. (Nasdaq:GILD) today announced that John C. Martin
PhD has been appointed Chairman of the Board of Directors, and John F.
Milligan, PhD has been appointed President.
Dr. Martin will continue to serve as Gilead´s
Chief Executive Officer. He is assuming the additional role of Chairman
of the Board from James M. Denny, who will remain a member of Gilead´s
Board of Directors, serving as lead director. Mr. Denny joined Gilead´s
Board in 1996 and was appointed Chairman in 2001. Dr. Milligan will
continue to serve as Gilead´s Chief Operating
Officer, in addition to his new role of President.
"I have had the honor of serving as the
Chairman of Gilead´s Board of Directors for
the past seven years and the opportunity to observe the leadership and
vision that John Martin and John Milligan both bring to Gilead," commented Mr. Denny. "I look forward to
working with them in their new roles as they continue to guide Gilead´s
efforts to bring novel therapies to patients affected by
life-threatening diseases around the world."
Dr. Martin joined Gilead in 1990 and was appointed President and Chief
Executive Officer in 1996. Prior to joining Gilead, Dr. Martin held
several leadership positions in the antiviral chemistry division at
Bristol-Myers Squibb and served for six years with Syntex Corporation
from 1978 until 1984. He is a member of the Presidential Advisory
Council on HIV/AIDS, the Board of Directors of Gen-Probe Incorporated
and the Board of Directors of the California Healthcare Institute.
Dr. Martin holds a PhD in organic chemistry from the University of
Chicago and an MBA in marketing from Golden Gate University.
Dr. Milligan also joined Gilead in 1990, beginning his career at the
company as a Research Scientist. He has held leadership roles in Project
Management and Corporate Development. In 2002, Dr. Milligan was
appointed Chief Financial Officer (CFO). He was named Chief Operating
Officer in 2007.
He holds a PhD in biochemistry from the University of Illinois and was
an American Cancer Society Postdoctoral fellow at the University of
California at San Francisco. Dr. Milligan was named "Bay
Area CFO of the Year" in 2006 for companies
with revenues greater than $500 million, and he was named the top
biotechnology industry CFO in the United States by Institutional
Investor magazine in 2006, 2007 and 2008.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company´s mission is to advance the
care of patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in North
America, Europe and Australia.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including risks
related to Gilead´s ability to develop and
deliver novel therapies to patients. The reader is cautioned not to rely
on these forward-looking statements. These and other risks are described
in detail in the Gilead Annual Report on Form 10-K for the year ended
December 31, 2007 as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead and Gilead assumes no obligation to update
any such forward-looking statements.
For more information on Gilead Sciences, please visit the company´s
website at www.gilead.com or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
